The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function.
Tegobuvir (TGV) is a novel non-nucleoside inhibitor (NNI) of HCV RNA replication with demonstrated antiviral activity in patients with genotype 1 chronic HCV infection. The mechanism of action of TGV has not been clearly defined despite the identification of resistance mutations mapping to the NS5B...
Guardado en:
Autores principales: | Christy M Hebner, Bin Han, Katherine M Brendza, Michelle Nash, Maisoun Sulfab, Yang Tian, Magdeleine Hung, Wanchi Fung, Randall W Vivian, James Trenkle, James Taylor, Kyla Bjornson, Steven Bondy, Xiaohong Liu, John Link, Johan Neyts, Roman Sakowicz, Weidong Zhong, Hengli Tang, Uli Schmitz |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/eeeef54f94cb49e4bd1ec7bb38024a99 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Structural and regulatory elements of HCV NS5B polymerase--β-loop and C-terminal tail--are required for activity of allosteric thumb site II inhibitors.
por: Sarah E Boyce, et al.
Publicado: (2014) -
Nucleosides, nucleotides & nucleic acids
Publicado: (2000) -
Non-canonical nucleosides and chemistry of the emergence of life
por: Sidney Becker, et al.
Publicado: (2018) -
First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients
por: Zahra Hasanshahi, et al.
Publicado: (2021) -
Engineered toxins "zymoxins" are activated by the HCV NS3 protease by removal of an inhibitory protein domain.
por: Assaf Shapira, et al.
Publicado: (2011)